Phase 3 Clinical Trials With Primary Completion Dates in December 2021
This is a list of Phase 3 trials with primary completion dates in December 2021 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ALLK | Allakos Inc. | 2021-12-01 | Phase 3 | NCT04322604 | A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis) |
| ATNM | Actinium Pharmaceuticals, Inc. | 2021-12-01 | Phase 3 | NCT02665065 | Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia |
| BCDA | BioCardia, Inc. | 2021-12-01 | Phase 3 | NCT02438306 | CardiAMP™ Cell Therapy Heart Failure Trial |
| ENDP | Endo International plc | 2021-12-01 | Phase 3 | NCT03526549 | Long-Term Study of EN3835 in Edematous Fibrosclerotic Panniculopathy (Cellulite) |
| GRTX | Galera Therapeutics, Inc. | 2021-12-01 | Phase 3 | NCT03689712 | ROMAN: A Study to Investigate the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer |
| KSPHF | Kissei Pharmaceutical Co., Ltd. | 2021-12-01 | Phase 3 | NCT04132050 | A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788 |
| LNTH | Lantheus Holdings, Inc. | 2021-12-01 | Phase 3 | NCT02764801 | Contrast-enhanced Ultrasound Evaluation of Chemoembolization |
| MCRB | Seres Therapeutics, Inc. | 2021-12-01 | Phase 3 | NCT03183141 | ECOSPOR IV: Open-Label Study, Including Study SERES-012 Extension, Evaluating SER-109 in Recurrent Clostridioides Difficile Infection |
| MDGL | Madrigal Pharmaceuticals, Inc. | 2021-12-01 | Phase 3 | NCT04197479 | A Phase 3 Study to Evaluate the Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease (NAFLD) Patients |
| MDGL | Madrigal Pharmaceuticals, Inc. | 2021-12-01 | Phase 3 | NCT03900429 | A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis |
| MGCLF | MGC Pharmaceuticals Limited | 2021-12-01 | Phase 3 | NCT04802382 | Clinical Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19 |
| NEPH | Nephros, Inc. | 2021-12-01 | Phase 3 | NCT04459338 | A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion |
| NKTR | Nektar Therapeutics | 2021-12-01 | Phase 3 | NCT03729245 | A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) |
| OPTN | OptiNose, Inc. | 2021-12-01 | Phase 3 | NCT03781804 | Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Sinusitis With or Without the Presence of Nasal Polyps |
| OPTN | OptiNose, Inc. | 2021-12-01 | Phase 3 | NCT03747458 | OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps |
| SAGE | Sage Therapeutics, Inc. | 2021-12-01 | Phase 3 | NCT04476030 | A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder |
| SLS | SELLAS Life Sciences Group, Inc. | 2021-12-01 | Phase 3 | NCT04229979 | GPS Compared With BAT in AML CR2/CR2p |
| SPPI | Spectrum Pharmaceuticals, Inc. | 2021-12-01 | Phase 3 | NCT01478542 | OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine |
| SRRA | Sierra Oncology, Inc. | 2021-12-01 | Phase 3 | NCT04173494 | A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Patients (MOMENTUM) |
| TARS | Tarsus Pharmaceuticals, Inc. | 2021-12-01 | Phase 3 | NCT04784091 | Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis |